Active substance
Propofol
- SFDA 21
- US FDA 14
- Health Canada 4
- US price lines 2
- WHO EML 1
- Safety 9
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ANESIA | 10.00 mg/ml | Emulsion for injection · Intravenous use | 5 Vial | SAR 58.60 | Generic · Prescription | Baxter | Valid |
| ANESIA | 10.00 mg/ml | Emulsion for injection · Intravenous use | 10 Vial | SAR 117.15 | Generic · Prescription | Baxter | Valid |
| DIPRIVAN VIAL 10MG-ML | 10 mg/ml | Emulsion for injection/infusion · Intravenous use | 5 Vial | SAR 110.05 | NCE · Prescription | ASPEN PHARMA TRADING LIMITED (APTL) | Valid |
| Novfol | 10 mg | Emulsion for infusion · Intravenous use | 5 Vial | SAR 85.10 | Generic · Prescription | PT. Novell Pharmaceutical Laboratories | Valid |
| PROPOFOL-LIPURO 0.5% EMULSION FOR Inj./Infusion | 0.5 % | Emulsion for injection/infusion · Intravenous use | 5 Vial | SAR 62.25 | NCE · Prescription | B. BRAUN | Valid |
| PROPOFOL-LIPURO 1%INJ OR INF VIAL | 1 % | Emulsion for injection/infusion · Intravenous use | 1 Bottle | SAR 37.70 | Generic · Prescription | B. BRAUN | Valid |
| PROPOFOL-LIPURO1% INJ OR INF AMPOULE | 1 % | Emulsion for injection/infusion · Intravenous use | 5 Ampoule | SAR 68.95 | Generic · Prescription | B. BRAUN | Valid |
| PROPOVEN 1% VIAL | 1 % | Emulsion for injection/infusion · Intravenous use | 10 Vial | SAR 461.70 | Generic · Prescription | Fresenius Kabi Deutschland GmbH | Valid |
| PROPOVEN 1% VIAL | 1 % | Emulsion for injection/infusion · Intravenous use | 5 Vial | SAR 102.90 | Generic · Prescription | Fresenius Kabi Deutschland GmbH | Valid |
| Propofol - Lipuro 1000 mg per 50 ml | 20 mg/ml | Emulsion for injection/infusion · Intravenous use | 10 Vial | SAR 629.60 | Generic · Prescription | B. BRAUN | Valid |
| Propoven | 20 mg/ml | Emulsion for injection/infusion · Intravenous use | 10 Vial | SAR 760.45 | Generic · Prescription | Fresenius Kabi Deutschland GmbH | Valid |
| RECOFOL 10MG-ML INJECTION | 10 mg/ml | Solution for injection · Intravenous use | 1 Vial | SAR 55.35 | Generic · Prescription | BAYER OY | Valid |
| RECOFOL 10MG-ML INJECTION | 10 mg/ml | Solution for injection · Intravenous use | 5 Ampoule | SAR 101.40 | Generic · Prescription | BAYER OY | Valid |
| RECOFOL 10MG-ML INJECTION | 10 mg/ml | Solution for injection · Intravenous use | 1 Vial | SAR 101.40 | Generic · Prescription | BAYER OY | Valid |
| RECOFOL 20MG-ML I.V. EMULSION FOR INFU | 20 mg/ml | Emulsion for infusion · Intravenous use | 1 Vial | SAR 80.05 | Generic · Prescription | BAYER OY | Valid |
| Sedafol | 10 mg/ml | Emulsion for infusion · Intravenous use | 1 Vial | SAR 17.00 | Generic · Prescription | Saudi Amarox | Valid |
| DIPRIVAN VIAL 10MG-ML | 10 mg/ml | Emulsion for injection/infusion · Intravenous use | 5 Vial | SAR 110.05 | NCE · Prescription | AstraZeneca | Withdrawn by MAH · Not Marketed |
| DIPRIVAN VIAL 10MG-ML | 10 mg/ml | Emulsion for injection/infusion · Intravenous use | 1 Vial | SAR 68.35 | Generic · Prescription | AstraZeneca | Withdrawn by MAH · Not Marketed |
| DIPRIVAN VIAL 10MG-ML | 10 mg/ml | Emulsion for injection/infusion · Intravenous use | 1 Vial | SAR 68.35 | Generic · Prescription | ASPEN PHARMA TRADING LIMITED (APTL) | Withdrawn by MAH · Not Marketed |
| PROPOFOL 1% I.V INJ OR INFUSION | 1 % | Emulsion for injection/infusion · Intravenous use | 5 Ampoule | SAR 102.90 | Generic · Prescription | FRESENIUS KABI | Withdrawn by MAH · Not Marketed |
| PROPOFOL-LIPURO 1%INJ OR INF VIAL | 1 % | Emulsion for injection/infusion · Intravenous use | 1 Bottle | SAR 68.95 | Generic · Prescription | B. BRAUN | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ANESTHESIA; BURN MANAGEMENT; STATUS EPILEPTICUS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| DIPRIVAN | 10MG/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 2 Oct 1989 |
| PROPOFOL | 10MG/ML | injectable · injection | SAGENT PHARMS INC | Prescription | 4 Jan 1999 |
| PROPOFOL | 10MG/ML | injectable · injection | HIKMA PHARMS | Prescription | 19 Apr 2005 |
| PROPOFOL | 10MG/ML | injectable · injection | HOSPIRA | Prescription | 17 Mar 2006 |
| PROPOFOL | 10MG/ML | injectable · injection | DR REDDYS | Prescription | 15 Nov 2018 |
| PROPOFOL | 10MG/ML | injectable · injection | INNOPHARMA | Prescription | 16 Sep 2020 |
| PROPOFOL | 10MG/ML | injectable · injection | AVET LIFESCIENCES | Prescription | 12 Oct 2021 |
| PROPOFOL | 10MG/ML | injectable · injection | ASPIRO | Prescription | 20 Jun 2024 |
| PROPOFOL | 10MG/ML | injectable · injection | AMNEAL | Prescription | 15 Aug 2024 |
| PROPOFOL | 10MG/ML | injectable · injection | EMERGE BIOSCIENCE | Prescription | 2 Dec 2025 |
| PROPOFOL | 10MG/ML | injectable · injection | ADAPTIS | Prescription | 14 Jul 2026 |
| DIPRIVAN | 10MG/ML | injectable · injection | FRESENIUS KABI USA | Discontinued | 2 Oct 1989 |
| PROPOFOL | 10MG/ML | injectable · injection | TEVA PARENTERAL | Discontinued | 19 Sep 2000 |
| PROPOFOL | 10MG/ML | injectable · injection | WATSON LABS INC | Discontinued | 22 Dec 2015 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| DIPRIVAN 1% | 02018950 | 10 MG / ML | EMULSION · INTRAVENOUS | ASPEN PHARMACARE CANADA INC. |
| PROPOFOL INJECTION | 02244379 | 10 MG / ML | EMULSION · INTRAVENOUS | BAXTER CORPORATION |
| PROPOFOL INJECTION | 02437643 | 10 MG / ML | EMULSION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| PROPOFOL INJECTION | 02525879 | 10 MG / ML | EMULSION · INTRAVENOUS | MARCAN PHARMACEUTICALS INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | PROPOFOL 200 MG/20 ML VIAL | $0.17094 | per ML | 2 Sep 2026 |
| US NADAC | PROPOFOL 500 MG/50 ML VIAL | $0.17094 | per ML | 19 Aug 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 1.1.2. General anaesthetics and oxygen > Injectable medicines · core
Anaesthetics and therapeutic gases
Parenteral > General injections > IV: 10 mg per mL; 20 mg per mL
Safety signals and safety-related labeling changes
- EMA PRAC 16 May 2024 PRAC signal: Hepatic failure
Action for MAH: update of the product information: Yes - EMA PRAC 11 Jan 2024 PRAC signal: Hepatic failure
Action for MAH: update of the product information: No - EMA PRAC 16 Mar 2023 PRAC signal: Medication errors that could potentially lead to life-threatening/fatal cases
Action for MAH: update of the product information: Yes - EMA PRAC 27 Oct 2022 PRAC signal: Medication errors that could potentially lead to life-threatening/fatal cases
Action for MAH: update of the product information: No - US FDA 31 Aug 2022 DIPRIVAN — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 12 Jan 2017 PRAC signal: Pharmacokinetic drug interaction leading to an increased propofol exposure
Action for MAH: update of the product information: Yes - EMA PRAC 29 Sep 2016 PRAC signal: Diabetes insipidus
Action for MAH: update of the product information: No - EMA PRAC 2 Sep 2016 PRAC signal: Pharmacokinetic drug interaction leading to an increased propofol exposure
Action for MAH: update of the product information: No - EMA PRAC 17 Mar 2016 PRAC signal: Diabetes insipidus
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.